263 related articles for article (PubMed ID: 22419002)
1. Advanced HCC: emerging molecular therapies.
Finn RS
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):25-34. PubMed ID: 22419002
[TBL] [Abstract][Full Text] [Related]
2. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Lencioni R; Chen XP; Dagher L; Venook AP
Oncologist; 2010; 15 Suppl 4():42-52. PubMed ID: 21115580
[TBL] [Abstract][Full Text] [Related]
4. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Lord R; Suddle A; Ross PJ
Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
6. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of hepatocellular carcinoma: are we making progress?
Roxburgh P; Evans TR
Adv Ther; 2008 Nov; 25(11):1089-104. PubMed ID: 18972075
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for hepatocellular carcinoma.
Sandhu DS; Tharayil VS; Lai JP; Roberts LR
Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the treatment response of HCC.
Kim KW; Lee JM; Choi BI
Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353
[TBL] [Abstract][Full Text] [Related]
10. Established and emerging therapies for hepatocellular carcinoma.
Cicinnati VR; Sotiropoulos GC; Beckebaum S
Minerva Med; 2010 Dec; 101(6):405-18. PubMed ID: 21196900
[TBL] [Abstract][Full Text] [Related]
11. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma.
Helmberger T; Dogan S; Straub G; Schrader A; Jüngst C; Reiser M; Waggershauser T; Jakobs T; Hoffmann RT; Löhe F; Graeb C; Rau HG; Schauer R; Jauch KW; Caselmann WH; Göke B; Jüngst D
Digestion; 2007; 75(2-3):104-12. PubMed ID: 17598962
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Yoo DJ; Kim KM; Jin YJ; Shim JH; Ko GY; Yoon HK; Sung KB; Lee JL; Kang YK; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2011 Jan; 26(1):145-54. PubMed ID: 21175808
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Hussain K; El-Serag HB
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):123-38. PubMed ID: 19305372
[TBL] [Abstract][Full Text] [Related]
14. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Irtan S; Chopin-Laly X; Ronot M; Faivre S; Paradis V; Belghiti J
Liver Int; 2011 May; 31(5):740-3. PubMed ID: 21457447
[TBL] [Abstract][Full Text] [Related]
15. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
[TBL] [Abstract][Full Text] [Related]
17. [Comparision of different interventional therapies for primary liver cancer].
Liu YM; Qin H; Wang CB; Fang XH; Ma QY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):232-5. PubMed ID: 17649645
[TBL] [Abstract][Full Text] [Related]
18. Medical therapies to extend survival in hepatocellular carcinoma.
Gish R; Marrero JB; Tong MJ
Clin Adv Hematol Oncol; 2008 Aug; 6(8):1-14; quiz 15. PubMed ID: 18833600
[TBL] [Abstract][Full Text] [Related]
19. Management of HCC.
de Lope CR; Tremosini S; Forner A; Reig M; Bruix J
J Hepatol; 2012; 56 Suppl 1():S75-87. PubMed ID: 22300468
[TBL] [Abstract][Full Text] [Related]
20. Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Gish RG; Abou-Alfa GK; Tong MJ
Clin Adv Hematol Oncol; 2010 Sep; 8(9):2 p preceding 4-15. PubMed ID: 21598749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
